The FDA has approved the combination of relakorilant (Lifyorli) with nab-paclitaxel (Abraxane) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This combination is intended for difficult-to-treat forms of these diseases. The approval was reported by MedPage Today. The drugs are given together in patients who do not respond to standard platinum chemotherapy. Relakorilant is a new drug approved in this combination. Nab-paclitaxel is a well-known chemotherapeutic drug bound to albumin, which improves the delivery of the active substance to cells. The approval expands treatment options for patients with advanced stages of ovarian cancer.